ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) – Research analysts at SVB Leerink decreased their Q2 2023 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research report issued on Tuesday, June 20th. SVB Leerink analyst R. Ruiz now anticipates that the company will earn ($0.13) per share for the quarter, down from their prior forecast of ($0.11). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.75) per share. SVB Leerink also issued estimates for ARS Pharmaceuticals’ Q3 2023 earnings at ($0.15) EPS, Q4 2023 earnings at ($0.26) EPS, FY2023 earnings at ($0.70) EPS, FY2024 earnings at ($0.80) EPS and FY2025 earnings at ($0.40) EPS.
ARS Pharmaceuticals Price Performance
Shares of NASDAQ:SPRY opened at $6.28 on Friday. The business’s 50 day simple moving average is $6.78 and its 200 day simple moving average is $7.29. ARS Pharmaceuticals has a 1 year low of $3.68 and a 1 year high of $9.65.
Insider Buying and Selling at ARS Pharmaceuticals
In other ARS Pharmaceuticals news, Director Laura Shawver sold 42,900 shares of the firm’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $5.31, for a total value of $227,799.00. Following the sale, the director now owns 210,346 shares of the company’s stock, valued at approximately $1,116,937.26. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 35.60% of the company’s stock.
Institutional Investors Weigh In On ARS Pharmaceuticals
A number of large investors have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new stake in shares of ARS Pharmaceuticals in the 1st quarter valued at $84,000. Prelude Capital Management LLC acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter valued at $98,000. State Street Corp boosted its holdings in shares of ARS Pharmaceuticals by 50.4% during the 1st quarter. State Street Corp now owns 129,191 shares of the company’s stock valued at $841,000 after acquiring an additional 43,300 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter valued at $895,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter valued at $1,825,000. Institutional investors and hedge funds own 56.12% of the company’s stock.
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Featured Articles
- Get a free research report on ARS Pharmaceuticals from StockNews.com
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Wayfair: From Steep Decline to Recent Surge
- Five stocks we like better than ARS Pharmaceuticals
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
